
EPINEX DIAGNOSTICS Stock
Epinex Diagnostics is a medical diagnostics company developing products for the identification of diabetes.
Sign up today and learn more about EPINEX DIAGNOSTICS Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About EPINEX DIAGNOSTICS Stock
Epinex Diagnostics specializes in the application of its unique expertise in medical diagnostics to target major deficiencies in the existing healthcare market by developing innovative rapid tests that address those unexploited markets. The Epinex business model is based on development of products that address key deficiencies in the existing market structure while staying within the boundaries of ‘established’ health care practices and manufacturing technology. This combination limits risk and maximizes earnings potential. Our expertise lies in identifying key areas within the healthcare field where a lack of easily-accessible diagnostic information exists. Epinex Diagnostics was founded in 2002 by three pioneers in the biomedical device industry with a combined experience of more than 70 years in biomedical engineering, product design and development, and medical device marketing. They have been joined by an advisory board of distinguished scientists, experts in marketing and management, and leaders in the field of diabetic care. Epinex Diagnostics, Inc. is located in Tustin, California, adjacent to the University of California, Irvine, in the heart of the Southern California biomedical industry.
Funding History
April 2008 | $1.2M |
---|---|
August 2010 | $599K |
April 2011 | $203K |
March 2013 | $318K |
January 2016 | $2.2M |
February 2016 | $100K |
Management
Vice President, Corporate Finance
Jeff Byrd
Chief Technology Officer
Henry J. Smith
President & CEO
Asad R. Zaidi
EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase